Free Trial

Arcus Biosciences (RCUS) Competitors

Arcus Biosciences logo
$8.23 -0.24 (-2.83%)
As of 07/7/2025 03:59 PM Eastern

RCUS vs. MLTX, MTSR, VKTX, KYMR, MOR, CRNX, ALVO, IMVT, CPRX, and HCM

Should you be buying Arcus Biosciences stock or one of its competitors? The main competitors of Arcus Biosciences include MoonLake Immunotherapeutics (MLTX), Metsera (MTSR), Viking Therapeutics (VKTX), Kymera Therapeutics (KYMR), MorphoSys (MOR), Crinetics Pharmaceuticals (CRNX), Alvotech (ALVO), Immunovant (IMVT), Catalyst Pharmaceuticals (CPRX), and HUTCHMED (HCM). These companies are all part of the "pharmaceutical products" industry.

Arcus Biosciences vs. Its Competitors

Arcus Biosciences (NYSE:RCUS) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, analyst recommendations, valuation, profitability, dividends and risk.

Arcus Biosciences currently has a consensus target price of $21.29, indicating a potential upside of 158.64%. MoonLake Immunotherapeutics has a consensus target price of $74.50, indicating a potential upside of 56.84%. Given Arcus Biosciences' higher probable upside, research analysts plainly believe Arcus Biosciences is more favorable than MoonLake Immunotherapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Arcus Biosciences
0 Sell rating(s)
2 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.89
MoonLake Immunotherapeutics
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
3.00

92.9% of Arcus Biosciences shares are held by institutional investors. Comparatively, 93.8% of MoonLake Immunotherapeutics shares are held by institutional investors. 9.6% of Arcus Biosciences shares are held by company insiders. Comparatively, 12.0% of MoonLake Immunotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Arcus Biosciences has a beta of 0.8, suggesting that its share price is 20% less volatile than the S&P 500. Comparatively, MoonLake Immunotherapeutics has a beta of 1.27, suggesting that its share price is 27% more volatile than the S&P 500.

MoonLake Immunotherapeutics has lower revenue, but higher earnings than Arcus Biosciences. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arcus Biosciences$258M3.38-$283M-$4.19-1.96
MoonLake ImmunotherapeuticsN/AN/A-$118.94M-$2.30-20.65

MoonLake Immunotherapeutics has a net margin of 0.00% compared to Arcus Biosciences' net margin of -258.94%. MoonLake Immunotherapeutics' return on equity of -30.81% beat Arcus Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Arcus Biosciences-258.94% -70.58% -32.97%
MoonLake Immunotherapeutics N/A -30.81%-28.40%

In the previous week, MoonLake Immunotherapeutics had 2 more articles in the media than Arcus Biosciences. MarketBeat recorded 3 mentions for MoonLake Immunotherapeutics and 1 mentions for Arcus Biosciences. MoonLake Immunotherapeutics' average media sentiment score of 0.89 beat Arcus Biosciences' score of -0.66 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Arcus Biosciences
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Negative
MoonLake Immunotherapeutics
2 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

MoonLake Immunotherapeutics beats Arcus Biosciences on 12 of the 16 factors compared between the two stocks.

Get Arcus Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for RCUS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RCUS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RCUS vs. The Competition

MetricArcus BiosciencesMED IndustryMedical SectorNYSE Exchange
Market Cap$896.85M$2.91B$5.52B$20.71B
Dividend YieldN/A2.44%5.24%3.72%
P/E Ratio-1.9620.4427.2627.80
Price / Sales3.38190.07381.2547.18
Price / CashN/A41.7026.2118.22
Price / Book1.557.397.944.59
Net Income-$283M-$55.04M$3.17B$982.91M
7 Day Performance-1.44%2.51%1.80%0.65%
1 Month Performance-17.66%-0.21%1.28%4.26%
1 Year Performance-40.53%3.41%33.57%13.93%

Arcus Biosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RCUS
Arcus Biosciences
2.7732 of 5 stars
$8.23
-2.8%
$21.29
+158.6%
-41.7%$896.85M$258M-1.96500
MLTX
MoonLake Immunotherapeutics
1.9777 of 5 stars
$47.20
-0.7%
$74.50
+57.8%
+13.0%$3.04BN/A-20.522Positive News
MTSR
Metsera
N/A$28.45
-0.5%
$55.00
+93.3%
N/A$3.00BN/A0.0081
VKTX
Viking Therapeutics
3.8404 of 5 stars
$26.50
-0.1%
$87.15
+228.9%
-46.3%$2.98BN/A-23.0420Gap Up
KYMR
Kymera Therapeutics
3.3151 of 5 stars
$43.64
-1.1%
$59.61
+36.6%
+44.8%$2.87B$47.07M-14.08170
MOR
MorphoSys
N/A$18.96
flat
N/AN/A$2.86B$238.28M-5.45730
CRNX
Crinetics Pharmaceuticals
3.1438 of 5 stars
$28.76
-4.0%
$74.56
+159.2%
-33.7%$2.81B$1.04M-7.53210
ALVO
Alvotech
3.998 of 5 stars
$9.12
-0.2%
$18.00
+97.4%
-25.6%$2.76B$491.98M24.651,032
IMVT
Immunovant
1.3806 of 5 stars
$16.00
-0.6%
$38.33
+139.6%
-38.9%$2.75BN/A-5.84120News Coverage
CPRX
Catalyst Pharmaceuticals
4.8936 of 5 stars
$21.70
-0.4%
$32.83
+51.3%
+37.9%$2.66B$491.73M13.8280Positive News
HCM
HUTCHMED
1.3161 of 5 stars
$15.05
-0.3%
$19.00
+26.2%
-16.5%$2.63B$630.20M0.001,811

Related Companies and Tools


This page (NYSE:RCUS) was last updated on 7/8/2025 by MarketBeat.com Staff
From Our Partners